Evrysdi is designed to treat SMA by increasing and sustaining the production of the survival motor neuron protein in the central nervous system and peripheral tissues.
Tibsovo is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia.
Said Darwazah, Hikma’s executive chairman and former CEO, will assume all CEO responsibilities; Hikma’s board has initiated the process to identify a new CEO.
A distinct set of PBM business practices have resulted in higher prices and delayed access to generics and biosimilars for patients, according to AAM CEO Dan Leonard.